Status
Conditions
Treatments
About
Purpose: Investigators propose a three-arm RCT across two military treatment facilities:1) in-person STAR-C, 2) telehealth STAR-C, and 3) no treatment control. Outcomes will be assessed immediately and at one- and three-months post treatment.
Hypothesis/Objectives: STAR-C, delivered in-person and via telehealth, will be effective in decreasing everyday cognitive complaints among patients with a history of mTBI. Effectiveness will be moderated by patient characteristics. Stakeholder feedback will yield a process map for broad implementation of STAR-C in varied clinical environments.
Full description
Specific Aim 1 (primary for RCT): To evaluate effectiveness of STAR-C.
Hypothesis 1a: In-Person STAR-C will lead to a greater decrease in everyday cognitive complaints (C4) compared to wait-list control.
Hypothesis 1b: Tele STAR-C will lead to a greater decrease in everyday cognitive complaints (C4) compared to wait-list control.
Specific Aim 2 (secondary): To evaluate maintenance of treatment effects using a practice based evidence approach.
Question 2a: What proportion of in-person STAR-C treatment effects (C4 and GAS) will be maintained at the 3-month follow-up?
Question 2b: What proportion of telehealth STAR-C treatment effects (C4 and GAS) will be maintained at the 3-month follow-up?
Specific Aim 3 (exploratory): To explore factors associated with heterogeneity in treatment response.
Question 3a: What factors prevented participants from achieving a ≥2-point improvement on the C4?
Question 3b: What factors prevented participants from maintaining ≥2-point improvement on the C4?
Question 3c: What factors prevented participants from achieving ≥2 out of 3 targets using GAS?
Question 3d: What factors contributed to participants maintaining or exceeding targets (GAS) at the 3-month follow-up?
Specific Aim 4 (implementation): Use stakeholder input (to include clinicians, administrators, and patients) from capacity assessment and after-action review to generate an implementation package for clinics interested in STAR-C.
Question 4: For what proportion of patients will clinicians rate STAR-C as acceptable, appropriate, and feasible (AIM/IAM/FIM)?
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
222 participants in 3 patient groups
Loading...
Central trial contact
Chad E Grills, Ph.D; Andrea Dvorak
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal